Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders.

Autor:	Symeonidis A; University of Patras Medical School, Hematology Division, Patras, Greece., Chondropoulos S; University General Hospital Attikon, Athens, Greece., Verigou E; Hematology Division, General University Hospital of Patras, Rion of Patras, Greece., Lazaris V; Hematology Division, General University Hospital of Patras, Rion of Patras, Greece., Kourakli A; Hematology Division, General University Hospital of Patras, Rion of Patras, Greece., Tsirigotis P; Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Aug 05; Vol. 12, pp. 884723. Date of Electronic Publication: 2022 Aug 05 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.884723
Abstrakt:	Chronic myelomonocytic leukemia (CMML) and the remaining, less frequent hybrid, mixed, or overlap myelodysplastic syndromes/myeloproliferative neoplasms (MDSs/MPNs) are difficult to treat neoplastic hematological disorders, exhibiting substantial clinical and prognostic heterogeneity, for which clear therapeutic guidelines or effective treatment options are still missing. CMML has an overall survival ranging from a few months to several years. Although patients with proliferative or dysplastic features may benefit from hydroxyurea and hypomethylating agent treatment, respectively, none of these treatments can establish long-term remission and prevent the inevitable transformation to acute leukemia. Novel targeted treatment approaches are emerging but are still under investigation. Therefore, currently, allogeneic stem cell transplantation (allo-SCT) remains the only treatment modality with a curative potential, but its widespread application is limited, due to significant morbidity and mortality associated with the procedure, especially in the elderly and in patients with comorbidities. Recognition of patient eligibility for allo-SCT is crucial, and the procedure should be addressed to patients with a good performance status without severe comorbidities and mainly to those in intermediate- to high-risk category, with a suitable stem cell donor available. The issues of best timing for performing transplantation, patient and donor eligibility, the type of conditioning regimen, and the outcomes after various allo-SCT procedures are the topics of this review. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Symeonidis, Chondropoulos, Verigou, Lazaris, Kourakli and Tsirigotis.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu